Everlab Raises $15M to Bring Preventive Health into the AI Era
Everlab offers a preventative health service that combines advanced diagnostics, continuous monitoring, and personalized care to detect diseases early.
Melbourne-based healthtech startup Everlab has raised a $15 million seed round led by Left Lane Capital to accelerate its international expansion and AI-driven platform. Co-founded by Dr. Steven Lu, Sam Kothari, Anshul Jain, and Marc Hermann, Everlab is reimagining preventive care by combining full-body diagnostics, proprietary AI, and clinical expertise to catch disease in people who still appear healthy.
The company is targeting the global chronic illness crisis with a model that blends deep data, advanced screening, and automation. “We believe everyone deserves access to world-class preventive care,” said CEO Marc Hermann. “By combining AI with the knowledge of leading clinicians, we’ve built a new kind of health platform designed to deliver smarter, earlier care to millions.”
From Clinic to Category-Definer
The idea for Everlab emerged when Kothari visited Dr. Lu’s Melbourne clinic following a family health scare. What began as a comprehensive personal check-up—DEXA scans, deep bloodwork, physical assessments—revealed early signs of heart disease and brittle bones in Kothari, then in his 30s. That initial experience led to a shared mission: make proactive care the standard.
Dr. Lu, frustrated by the reactive nature of traditional medicine, had already been experimenting with more thorough, tech-enabled diagnostics. Kothari brought operational know-how from Airwallex. They later teamed up with Jain and Hermann, uniting around the goal of building scalable infrastructure for preventive medicine—labs, software, and AI working in tandem to detect risk early and personalize care.
AI That Cuts Through the Noise
At its core, Everlab consolidates health records—lab results, lifestyle data, imaging—into a digital platform that uses AI agents to analyze over a million biomarkers. Physicians still sign off, but AI reduces their workload dramatically. “The time it takes me goes from 30 minutes to 3 or 4 minutes,” Dr. Lu said.
The platform pulls in 20 years of pathology data where possible, helping doctors see trends rather than isolated metrics. “We don’t need GPs to sift through 20 years of PDF fax reports,” said Kothari.
One in four test results analyzed by Everlab are abnormal. For 2.5% of users, the results have been life-altering—uncovering blocked arteries, early-stage cancers, gastrointestinal tumors, and more.
Scaling from Australia to the World
Everlab offers two tiers of membership: a $3,000 annual plan with full diagnostic and lifestyle support, and a $1,500 option focused on medical insights. The company claims tens of thousands are on its waitlist and expects 20x growth in the year ahead.
The seed funding will help expand Everlab’s clinical network, engineering team, and AI capabilities. “Preventive care has always been a medical ideal but rarely a commercial reality,” said Laura Sillman of Left Lane Capital. “Everlab has built a product and model that makes it scalable.”
While Australia’s healthcare regulations provide a strong foundation, Everlab’s ambitions are global—particularly in Asia, where Kothari sees a looming metabolic health crisis. “We’re all running into this,” he said. “We want to help societies shift—starting in Australia, and scaling to the U.S., U.K., and beyond.”
Read more on Forbes Australia
Listen to Emil Eriksen with David Ronick on the Venture Everywhere podcast: &you and Me. Now on Apple & Spotify and check out all our past episodes here!
